ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 8,851 Shares of Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 8,851 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $73,286.28. Following the transaction, the chief financial officer now owns 106,764 shares of the company’s stock, valued at $884,005.92. The trade was a 7.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

ORIC Pharmaceuticals Price Performance

Shares of ORIC Pharmaceuticals stock opened at $8.25 on Wednesday. The company has a market capitalization of $582.18 million, a price-to-earnings ratio of -4.58 and a beta of 1.13. The business has a fifty day simple moving average of $9.35 and a two-hundred day simple moving average of $9.37. ORIC Pharmaceuticals, Inc. has a 1 year low of $6.33 and a 1 year high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.01). As a group, equities analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ORIC Pharmaceuticals

A number of institutional investors have recently modified their holdings of ORIC. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of ORIC Pharmaceuticals in the second quarter valued at approximately $724,000. Bank of New York Mellon Corp raised its position in shares of ORIC Pharmaceuticals by 62.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 186,484 shares of the company’s stock valued at $1,318,000 after buying an additional 71,394 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ORIC Pharmaceuticals by 162.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock valued at $36,000 after purchasing an additional 3,188 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of ORIC Pharmaceuticals by 53.7% in the 2nd quarter. Rhumbline Advisers now owns 92,702 shares of the company’s stock valued at $655,000 after purchasing an additional 32,402 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of ORIC Pharmaceuticals by 8.3% in the 2nd quarter. Victory Capital Management Inc. now owns 95,850 shares of the company’s stock valued at $678,000 after purchasing an additional 7,310 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ORIC. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Monday, September 23rd. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a report on Monday, November 4th. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. Wells Fargo & Company initiated coverage on ORIC Pharmaceuticals in a research report on Thursday, October 31st. They set an “overweight” rating and a $20.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of ORIC Pharmaceuticals in a research report on Friday, September 6th. They set a “buy” rating and a $20.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $18.29.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.